Upadhayay Shubham, Soni Divya, Dhureja Maanvi, Temgire Pooja, Kumar Vishal, Arthur Richmond, Kumar Puneet
Department of Pharmacology, Central University of Punjab, Ghudda, Bathinda, Punjab, 151401, India.
Mol Neurobiol. 2025 Apr 26. doi: 10.1007/s12035-025-04962-x.
In the last few decades, the incidence and progression of neurological disorders have consistently increased, which mainly occur due to environmental pollution, genetic abnormalities, and modern lifestyles. Several case reports suggested that these factors enhanced oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, leading to neurological disease. The pathophysiology of neurological disorders is still not understood, mainly due to the diversity within affected populations. Existing treatment options primarily provide symptomatic relief but frequently come with considerable side effects, including depression, anxiety, and restlessness. Fibroblast growth factors (FGFs) are key signalling molecules regulating various cellular functions, including cell proliferation, differentiation, electrical excitability, and injury responses. Hence, several investigations claimed a relationship between FGFs and neurological disorders, and their findings indicated that they could be used as therapeutic targets for neurological disorders. The FGFs are reported to activate various signalling pathways, including Ras/MAPK/PI3k/Akt, and downregulate the GSK-3β/NF-κB pathways responsible for anti-oxidant, anti-inflammatory, and anti-apoptotic effects. Therefore, researchers are interested in developing novel treatment options for neurological disorders. The emergence of unreported FGFs contributes to our understanding of their involvement in these conditions and encourages further exploration of innovative therapeutic approaches. All the data were obtained from published articles using PubMed, Web of Science, and Scopus databases using the search terms Fibroblast Growth Factor, PD, HD, AD, ALS, signalling pathways, and neurological disorders.
在过去几十年中，神经系统疾病的发病率和病情进展持续上升，这主要是由环境污染、基因异常和现代生活方式导致的。一些病例报告表明，这些因素会增强氧化应激、线粒体功能障碍、炎症和细胞凋亡，从而引发神经系统疾病。神经系统疾病的病理生理学仍未完全明确，主要原因是受影响人群的多样性。现有的治疗方法主要是缓解症状，但常常伴有相当多的副作用，包括抑郁、焦虑和烦躁不安。成纤维细胞生长因子（FGFs）是调节各种细胞功能的关键信号分子，包括细胞增殖、分化、电兴奋性和损伤反应。因此，多项研究表明FGFs与神经系统疾病之间存在关联，其研究结果表明它们可用作神经系统疾病的治疗靶点。据报道，FGFs可激活多种信号通路，包括Ras/MAPK/PI3k/Akt，并下调负责抗氧化、抗炎和抗凋亡作用的GSK-3β/NF-κB通路。因此，研究人员对开发治疗神经系统疾病的新方法很感兴趣。未报道的FGFs的出现有助于我们了解它们在这些疾病中的作用，并鼓励进一步探索创新的治疗方法。所有数据均从使用PubMed、Web of Science和Scopus数据库发表的文章中获取，搜索词为成纤维细胞生长因子、帕金森病、亨廷顿病、阿尔茨海默病、肌萎缩侧索硬化症、信号通路和神经系统疾病。
